Divergent structure-activity relationships of structurally similar acetylcholinesterase inhibitors

Journal of Medicinal Chemistry

Volumn 56, Issue 19, 2013, Pages 7615-7624

  Andersson, C David ^a   Forsgren, Nina ^b   Akfur, Christine ^b   Allgardsson, Anders ^b   Berg, Lotta ^a   Engdahl, Cecilia ^a,b   Qian, Weixing ^a   Ekström, Fredrik ^b   Linusson, Anna ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b SWEDISH DEFENCE RESEARCH AGENCY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4 DICHLOROPHENYL) N [2 (DIETHYLAMINO)ETHYL]METHANESULFONAMIDE; 1 (4 CHLOROPHENYL) N [2 (DIETHYLAMINO)ETHYL]METHANESULFONAMIDE; 3 CHLORO N (2 DIETHYLAMINOETHYL)BENZENESULFONAMIDE; 4 (2 CHLORO 6 NITROPHENOXY) N (2 DIETHYLAMINOETHYL)BENZENESULFONAMIDE; 4 CHLORANYL N [2 (DIETHYLAMINO)ETHYL] 2 FLUORANYLBENZENESULFONAMIDE; 4 CHLORANYL N [2 (DIETHYLAMINO)ETHYL]BENZENESULFONAMIDE; 4' CHLOROBIPHENYL 4 SULFONIC ACID (2 DIETHYLAMINOETHYL)AMIDE; ACETYLCHOLINESTERASE; C (4 BROMOPHENYL) N (2 DIETHYLAMINOETHYL)METHANESULFONAMIDE; CHOLINESTERASE INHIBITOR; N (2 DIETHYLAMINOETHYL) C (4 TRIFLUOROMETHYLPHENYL)METHANESULFONAMIDE; N [2 (DIETHYLAMINO)ETHYL] 1 (4 FLUOROPHENYL)METHANESULFONAMIDE; N [2 (DIETHYLAMINO)ETHYL] 1 (4 METHYLPHENYL)METHANESULFONAMIDE; N [2 (DIETHYLAMINO)ETHYL] 1 PHENYLMETHANESULFONAMIDE; N [2 (DIETHYLAMINO)ETHYL] 2 FLUORANYLBENZENESULFONAMIDE; N [2 (DIETHYLAMINO)ETHYL] 3 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; N [2 (DIETHYLAMINO)ETHYL] 3 METHOXYBENZENESULFONAMIDE; N [2 (DIETHYLAMINO)ETHYL] 3,4 DIFLUORANYLBENZENESULFONAMIDE; N [2 (DIETHYLAMINO)ETHYL] 4 FLUORANYLBENZENESULFONAMIDE; N [2 (DIETHYLAMINO)ETHYL] 4 METHOXYBENZENESULFONAMIDE; N [2 (DIETHYLAMINO)ETHYL] 4 METHYLBENZENESULFONAMIDE; N [2 (DIETHYLAMINO)ETHYL] 4 NITROBENZENESULFONAMIDE; N [2 (DIETHYLAMINO)ETHYL]BENZENEMETHANESULFONAMIDE DERIVATIVE; N [2 (DIETHYLAMINO)ETHYL]BENZENESULFONAMIDE; N [2 (DIETHYLAMINO)ETHYL]BENZENESULFONAMIDE DERIVATIVE; NAPHTALENE 1 SULFONIC ACID (2 DIETHYLAMINOETHYL)AMIDE; NAPHTALENE 2 SULFONIC ACID (2 DIETHYLAMINOETHYL)AMIDE; SULFONAMIDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENTHALPY; ENTROPY; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HYDROLYSIS; IC 50; MOLECULAR INTERACTION; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS; X RAY CRYSTALLOGRAPHY;

ACETYLCHOLINESTERASE; ANIMALS; BENZENE DERIVATIVES; BINDING SITES; BIPHENYL COMPOUNDS; CHOLINESTERASE INHIBITORS; CRYSTALLOGRAPHY, X-RAY; ENZYME ASSAYS; ENZYME REACTIVATORS; HYDROLYSIS; MICE; MOLECULAR STRUCTURE; NAPHTHALENES; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; THERMODYNAMICS;

EID: 84885571953     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400990p     Document Type: Article

References (59)

1. Taylor, J. L.; Mayer, R. T.; Himel, C. M. Conformers of acetylcholinesterase-a mechanism of allosteric control Mol. Pharmacol. 1994, 45, 74-83
2. Holzgrabe, U.; Kapkova, P.; Alptuzun, V.; Scheiber, J.; Kugelmann, E. Targeting acetylcholinesterase to treat neurodegeneration Expert Opin. Ther. Targets 2007, 11, 161-179
3. Perry, E. K.; Perry, R. H.; Blessed, G.; Tomlinson, B. E. Changes in brain cholinesterases in senile dementia of Alzheimer type Neuropathol. Appl. Neurobiol. 1978, 4, 273-277
4. Talesa, V. N. Acetylcholinesterase in Alzheimer's disease Mech. Ageing Dev. 2001, 122, 1961-1969
5. Johannsen, P. Long-term cholinesterase inhibitor treatment of Alzheimer's disease CNS Drugs 2004, 18, 757-768
6. Jackson, S.; Ham, R. J.; Wilkinson, D. The safety and tolerability of donepezil in patients with Alzheimer's disease Br. J. Clin. Pharmacol. 2004, 58, 1-8
7. de Koning, M. C.; Joosen, M. J. A.; Noort, D.; van Zuylen, A.; Tromp, M. C. Peripheral site ligand-oxime conjugates: a novel concept towards reactivation of nerve agent-inhibited human acetylcholinesterase Bioorg. Med. Chem. 2011, 19, 588-594
8. Bourne, Y.; Taylor, P.; Radić, Z.; Marchot, P. Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site EMBO J. 2003, 22, 1-12
9. Sussman, J. L.; Harel, M.; Frolow, F.; Oefner, C.; Goldman, A.; Toker, L.; Silman, I. Atomic-structure of acetylcholinesterase from Torpedo-californica-a prototypic acetylcholine-binding protein Science 1991, 253, 872-879
10. Cheung, J.; Rudolph, M. J.; Burshteyn, F.; Cassidy, M. S.; Gary, E. N.; Love, J.; Franklin, M. C.; Height, J. J. Structures of human acetylcholinesterase in complex with pharmacologically important ligands J. Med. Chem. 2012, 55, 10282-10286
11. Eskander, M. F.; Nagykery, N. G.; Leung, E. Y.; Khelghati, B.; Geula, C. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles Brain Res. 2005, 1060, 144-152
12. Galdeano, C.; Viayna, E.; Arroyo, P.; Bidon-Chanal, A.; Blas, J. R.; Munoz-Torrero, D.; Luque, F. J. Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents Curr. Pharm. Des. 2010, 16, 2818-2836
13. Zhang, R. W.; Tang, X. C.; Han, Y. Y.; Sang, G. W.; Zhang, Y. D.; Ma, Y. X.; Zhang, C. L.; Yang, R. M. Drug-evaluation of huperzine-a in the treatment of senile memory disorders Acta Pharm. Sin. 1991, 12, 250-252
14. Wang, R.; Yan, H.; Tang, X. C. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine Acta Pharmacol. Sin. 2006, 27, 1-26
15. Radić, Z.; Taylor, P. Interaction kinetics of reversible inhibitors and substrates with acetylcholinesterase and its fasciculin 2 complex J. Biol. Chem. 2001, 276, 4622-4633
16. Carlier, P. R.; Han, Y. F.; Chow, E. S. H.; Li, C. P. L.; Wang, H.; Lieu, T. X.; Wong, H. S.; Pang, Y. P. Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis Bioorg. Med. Chem. 1999, 7, 351-357
17. Savini, L.; Campiani, G.; Gaeta, A.; Pellerano, C.; Fattorusso, C.; Chiasserini, L.; Fedorko, J. M.; Saxena, A. Novel and potent tacrine-related hetero- and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase Bioorg. Med. Chem. Lett. 2001, 11, 1779-1782
18. Savini, L.; Gaeta, A.; Fattorusso, C.; Catalanotti, B.; Campiani, G.; Chiasserini, L.; Pellerano, C.; Novellino, E.; McKissic, D.; Saxena, A. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors J. Med. Chem. 2003, 46, 1-4
19. Campiani, G.; Fattorusso, C.; Butini, S.; Gaeta, A.; Agnusdei, M.; Gemma, S.; Persico, M.; Catalanotti, B.; Savini, L.; Nacci, V.; Novellino, E.; Holloway, H. W.; Greig, N. H.; Belinskaya, T.; Fedorko, J. M.; Saxena, A. Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors J. Med. Chem. 2005, 48, 1919-1929
20. Rydberg, E. H.; Brumshtein, B.; Greenblatt, H. M.; Wong, D. M.; Shaya, D.; Williams, L. D.; Carlier, P. R.; Pang, Y. P.; Silman, I.; Sussman, J. L. Complexes of alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: binding of bis(5)-tacrine produces a dramatic rearrangement in the active-site gorge J. Med. Chem. 2006, 49, 5491-5500
21. Lewis, W. G.; Green, L. G.; Grynszpan, F.; Radić, Z.; Carlier, P. R.; Taylor, P.; Finn, M. G.; Sharpless, K. B. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks Angew. Chem., Int. Ed. 2002, 41, 1053-1057
22. Bourne, Y.; Kolb, H. C.; Radić, Z.; Sharpless, K. B.; Taylor, P.; Marchot, P. Freeze-frame inhibitor captures acetylcholinesterase in a unique conformation Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 1449-1454
23. Villalobos, A.; Blake, J. F.; Biggers, C. K.; Butler, T. W.; Chapin, D. S.; Chen, Y. P. L.; Ives, J. L.; Jones, S. B.; Liston, D. R.; Nagel, A. A.; Nason, D. M.; Nielsen, J. A.; Shalaby, I. A.; White, W. F. Novel benzisoxazole derivatives as potent and selective inhibitors of acetylcholinesterase J. Med. Chem. 1994, 37, 2721-2734
24. Nagel, A. A.; Liston, D. R.; Jung, S.; Mahar, M.; Vincent, L. A.; Chapin, D.; Chen, Y. L.; Hubbard, S.; Ives, J. L.; Jones, S. B.; Nielsen, J. A.; Ramirez, A.; Shalaby, I. A.; Villalobos, A.; White, W. F. Design and synthesis of 1-heteroaryl-3-(1-benzyl-4-piperidinyl)propan-1-one derivatives as potent, selective acetylcholinesterase inhibitors J. Med. Chem. 1995, 38, 1084-1089
25. Kryger, G.; Silman, I.; Sussman, J. L. Structure of acetylcholinesterase complexed with E2020 (Aricept (R)): implications for the design of new anti-Alzheimer drugs Structure 1999, 7, 297-307
26. Sugimoto, H.; Yamanishi, Y.; Iimura, Y.; Kawakami, Y. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors Curr. Med. Chem. 2000, 7, 303-339
27. Ishichi, Y.; Sasaki, M.; Setoh, M.; Tsukamoto, T.; Miwatashi, S.; Nagabukuro, H.; Okanishi, S.; Imai, S.; Saikawa, R.; Doi, T.; Ishihara, Y. Novel acetylcholinesterase inhibitor as increasing agent on rhythmic bladder contractions: SAR of 8-{3-[1-(3-fluorobenzyl)piperidin-4-yl]propanoyl}-1,2,5,6- tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (TAK-802) and related compounds Bioorg. Med. Chem. 2005, 13, 1901-1911
28. Artursson, E.; Andersson, P. O.; Akfur, C.; Linusson, A.; Börjegren, S.; Ekström, F. Catalytic-site conformational equilibrium in nerve-agent adducts of acetylcholinesterase: Possible implications for the HI-6 antidote substrate specificity Biochem. Pharmacol. 2013, 85, 1389-1397
29. Ekström, F.; Hörnberg, A.; Artursson, E.; Hammarström, L. G.; Schneider, G.; Pang, Y. P. Structure of HI-6 center dot sarin- Acetylcholinesterase determined by X-Ray crystallography and molecular dynamics simulation: reactivator mechanism and design PLoS One 2009, 4, e5957
30. Kaur, J.; Zhang, M. Q. Molecular modelling and QSAR of reversible acetylcholinesterase inhibitors Curr. Med. Chem. 2000, 7, 273-294
31. Bolognesi, M. L.; Minarini, A.; Tumiatti, V.; Melchiorre, C. Progress in acetylcholinesterase inhibitors for Alzheimer's disease Expert Opin. Ther. Pat. 2006, 16, 811-823
32. Tumiattit, V.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Milelli, A.; Matera, R.; Melchiorre, C. Progress in acetylcholinesterase inhibitors for Alzheimer's disease: an update Expert Opin. Ther. Pat. 2008, 18, 387-401
33. Saxena, A.; Fedorko, J. M.; Vinayaka, C. R.; Medhekar, R.; Radić, Z.; Taylor, P.; Lockridge, O.; Doctor, B. P. Aromatic amino-acid residues at the active and peripheral anionic sites control the binding of E2020 (Aricept (R)) to cholinesterases Eur. J. Biochem. 2003, 270, 4447-4458
34. Lee, E. C.; Kim, D.; Jurecka, P.; Tarakeshwar, P.; Hobza, P.; Kim, K. S. Understanding of assembly phenomena by aromatic-aromatic interactions: benzene dimer and the substituted systems J. Phys. Chem. A 2007, 111, 3446-3457
35. Rizzo, S.; Bartolini, M.; Ceccarini, L.; Piazzi, L.; Gobbi, S.; Cavalli, A.; Recanatini, M.; Andrisano, V.; Rampa, A. Targeting Alzheimer's disease: novel indanone hybrids bearing a pharmacophoric fragment of AP2238 Bioorg. Med. Chem. 2010, 18, 1749-1760
36. Sugimoto, H.; Tsuchiya, Y.; Sugumi, H.; Higurashi, K.; Karibe, N.; Iimura, Y.; Sasaki, A.; Kawakami, Y.; Nakamura, T.; Araki, S.; Yamanishi, Y.; Yamatsu, K. Novel piperidine-derivatives-Synthesis and antiacetylcholinesterase activity of 1-benzyl-4-[2-(N -benzoylamino)ethyl]piperidine derivatives J. Med. Chem. 1990, 33, 1880-1887
37. Kwon, Y. E.; Park, J. Y.; No, K. T.; Shin, J. H.; Lee, S. K.; Eun, J. S.; Yang, J. H.; Shin, T. Y.; Kim, D. K.; Chae, B. S.; Leem, J. Y.; Kim, K. H. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and A beta(1-42) aggregation for Alzheimer's disease therapeutics Bioorg. Med. Chem. 2007, 15, 6596-6607
38. Piazzi, L.; Cavalli, A.; Belluti, F.; Bisi, A.; Gobbi, S.; Rizzo, S.; Bartolini, M.; Andrisano, V.; Recanatini, M.; Rampa, A. Extensive SAR and computational studies of 3-{4-[(benzylmethylamino)methyl]phenyl}-6,7-dimethoxy-2 H -2-chromenone (AP2238) derivatives J. Med. Chem. 2007, 50, 4250-4254
39. Cockroft, S. L.; Perkins, J.; Zonta, C.; Adams, H.; Spey, S. E.; Low, C. M. R.; Vinter, J. G.; Lawson, K. R.; Urch, C. J.; Hunter, C. A. Substituent effects on aromatic stacking interactions Org. Biomol. Chem. 2007, 5, 1062-1080
40. Arnstein, S. A.; Sherrill, C. D. Substituent effects in parallel-displaced pi-pi interactions Phys. Chem. Chem. Phys. 2008, 10, 2646-2655
41. Ringer, A. L.; Sinnokrot, M. O.; Lively, R. P.; Sherrill, C. D. The effect of multiple substituents on sandwich and T-Shaped pi-pi interactions Chem.-Eur. J. 2006, 12, 3821-3828
42. Berg, L.; Andersson, C. D.; Artursson, E.; Hörnberg, A.; Tunemalm, A. K.; Linusson, A.; Ekström, F. Targeting acetylcholinesterase: identification of chemical leads by high throughput screening, structure determination and molecular modeling PLoS One 2011, 6, e26039
43. Ellman, G. L.; Courtney, K. D.; Andres, V.; Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 1961, 7, 88-95
44. Araújo, J. Q.; de Brito, M. A.; Hoelz, L. V. B.; de Alencastro, R. B.; Castro, H. C.; Rodrigues, C. R.; Albuquerque, M. G. Receptor-dependent (RD) 3D-QSAR approach of a series of benzylpiperidine inhibitors of human acetylcholinesterase (HuAChE) Eur. J. Med. Chem. 2011, 46, 39-51
45. Biela, A.; Nasief, N. N.; Betz, M.; Heine, A.; Hangauer, D.; Klebe, G. Dissecting the hydrophobic effect on the molecular level: the role of water, enthalpy, and entropy in ligand binding to thermolysin Angew. Chem., Int. Ed. 2013, 52, 1822-1828
46. Reynolds, C. H.; Holloway, M. K. Thermodynamics of ligand binding and efficiency ACS Med. Chem. Lett. 2011, 2, 433-437
47. Berg, L.; Niemiec, M. S.; Qian, W. X.; Andersson, C. D.; Wittung-Stafshede, P.; Ekström, F.; Linusson, A. Similar but different: thermodynamic and structural characterization of a pair of enantiomers binding to acetylcholinesterase Angew. Chem., Int. Ed. 2012, 51, 12716-12720
48. Seo, J. I.; Kim, I.; Lee, Y. S. Pi-pi Interaction energies in monosubstituted-benzene dimers in parallel- and antiparallel-displaced conformations Chem. Phys. Lett. 2009, 474, 101-106
49. Wallnoefer, H. G.; Fox, T.; Liedl, K. R.; Tautermann, C. S. Dispersion dominated halogen-pi interactions: energies and locations of minima Phys. Chem. Chem. Phys. 2010, 12, 14941-14949
50. Matter, H.; Nazare, M.; Gussregen, S.; Will, D. W.; Schreuder, H.; Bauer, A.; Urmann, M.; Ritter, K.; Wagner, M.; Wehner, V. Evidence for C-Cl/C-Br···pi Interactions as an important contribution to protein-ligand binding affinity Angew. Chem., Int. Ed. 2009, 48, 2911-2916
51. Ekström, F.; Pang, Y. P.; Boman, M.; Artursson, E.; Akfur, C.; Börjegren, S. Crystal structures of acetylcholinesterase in complex with HI-6, Ortho-7 and obidoxime: structural basis for differences in the ability to reactivate tabun conjugates Biochem. Pharmacol. 2006, 72, 597-607
52. Origin SR4 7.0552; Origin Lab Corporation, Northampton, MA.
53. Ekström, F.; Akfur, C.; Tunemalm, A. K.; Lundberg, S. Structural changes of phenylalanine 338 and histidine 447 revealed by the crystal structures of tabun-inhibited murine acetylcholinesterase Biochemistry 2006, 45, 74-81
54. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants J. Appl. Crystallogr. 1993, 26, 795-800
55. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255
56. Adams, P. D.; Grosse-Kunstleve, R. W.; Hung, L. W.; Ioerger, T. R.; McCoy, A. J.; Moriarty, N. W.; Read, R. J.; Sacchettini, J. C.; Sauter, N. K.; Terwilliger, T. C. PHENIX: building new software for automated crystallographic structure determination Acta Crystallogr., Sect. D: Biol. Crystallogr. 2002, 58, 1948-1954
57. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132
58. Vriend, G. WHAT IF: a molecular modelling and drug design program J. Mol. Graphics 1990, 8, 52-56
59. DeLano, W. L. The PyMOL Molecular Graphics System, Schrödinger, New York, 2002